248 related articles for article (PubMed ID: 31266670)
1. Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources.
Adrien N; Hyde TB; Gacic-Dobo M; Hombach J; Krishnaswamy A; Lambach P
Vaccine; 2019 Jul; 37(32):4511-4517. PubMed ID: 31266670
[TBL] [Abstract][Full Text] [Related]
2. Global Risk and Elimination of Yellow Fever Epidemics.
Ndeffo-Mbah ML; Pandey A
J Infect Dis; 2020 Jun; 221(12):2026-2034. PubMed ID: 31545372
[TBL] [Abstract][Full Text] [Related]
3. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.
Fisker AB; Ravn H; Rodrigues A; Østergaard MD; Bale C; Benn CS; Aaby P
Vaccine; 2014 Jan; 32(5):598-605. PubMed ID: 24325827
[TBL] [Abstract][Full Text] [Related]
5. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
[TBL] [Abstract][Full Text] [Related]
6. Eliminating yellow fever epidemics in Africa: Vaccine demand forecast and impact modelling.
Jean K; Hamlet A; Benzler J; Cibrelus L; Gaythorpe KAM; Sall A; Ferguson NM; Garske T
PLoS Negl Trop Dis; 2020 May; 14(5):e0008304. PubMed ID: 32379756
[TBL] [Abstract][Full Text] [Related]
7. Yellow fever vaccine for patients with HIV infection.
Barte H; Horvath TH; Rutherford GW
Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
[TBL] [Abstract][Full Text] [Related]
8. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
Front Immunol; 2020; 11():577751. PubMed ID: 33133096
[No Abstract] [Full Text] [Related]
9. Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children.
Idoko OT; Mohammed N; Ansah P; Hodgson A; Tapia MD; Sow SO; Chowdhury PR; Niedrig M; Saathoff E; Kampmann B
Expert Rev Vaccines; 2019 Aug; 18(8):867-875. PubMed ID: 31269829
[No Abstract] [Full Text] [Related]
10. Yellow fever vaccine: an effective vaccine for travelers.
Verma R; Khanna P; Chawla S
Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
[TBL] [Abstract][Full Text] [Related]
11. Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa?
Baba MM; Ikusemoran M
Biochem Biophys Res Commun; 2017 Oct; 492(4):548-557. PubMed ID: 28109882
[TBL] [Abstract][Full Text] [Related]
12. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
13. Sanger-based sequencing technology for yellow fever vaccine genetic quality control.
Pestana CP; Lawson-Ferreira R; Lessa-Aquino C; Leal MDLF; Freire MDS; Homma A; Medeiros MA
J Virol Methods; 2018 Oct; 260():82-87. PubMed ID: 30009851
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.
Roy Chowdhury P; Meier C; Laraway H; Tang Y; Hodgson A; Sow SO; Enwere GC; Plikaytis BD; Kulkarni PS; Preziosi MP; Niedrig M
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S586-93. PubMed ID: 26553692
[TBL] [Abstract][Full Text] [Related]
15. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria.
Monath TP; Nasidi A
Am J Trop Med Hyg; 1993 Feb; 48(2):274-99. PubMed ID: 8447531
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
[TBL] [Abstract][Full Text] [Related]
17. Incidence, drivers and global health implications of the 2019/2020 yellow fever sporadic outbreaks in Sub-Saharan Africa.
Uchenna Emeribe A; Nasir Abdullahi I; O R Ajagbe O; Egede Ugwu C; Oloche Onoja S; Dahiru Abubakar S; Modesta Umeozuru C; Sunday Animasaun O; Omoruyi Omosigho P; Mukhtar Danmusa U; Alhaji Baba Mallam M; Saidu Aminu M; Yahaya H; Oyewusi S
Pathog Dis; 2021 Apr; 79(4):. PubMed ID: 33739369
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
19. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
[TBL] [Abstract][Full Text] [Related]
20. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
